Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Abstract Background The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pediatric acute B-lymphoblastic leukemia (B-ALL). The BCR-ABL tyrosine ki...

Full description

Bibliographic Details
Main Authors: Xinhua Xiao, Ping Liu, Donghe Li, Zhizhou Xia, Peihong Wang, Xiuli Zhang, Mingzhu Liu, Lujian Liao, Bo Jiao, Ruibao Ren
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Journal of Hematology & Oncology
Subjects:
Ph+ B-ALL
JNK
Dasatinib
Combination target therapy
Online Access:http://link.springer.com/article/10.1186/s13045-020-00912-3

Internet

http://link.springer.com/article/10.1186/s13045-020-00912-3

Similar Items